JP2018524270A5 - - Google Patents

Download PDF

Info

Publication number
JP2018524270A5
JP2018524270A5 JP2017558675A JP2017558675A JP2018524270A5 JP 2018524270 A5 JP2018524270 A5 JP 2018524270A5 JP 2017558675 A JP2017558675 A JP 2017558675A JP 2017558675 A JP2017558675 A JP 2017558675A JP 2018524270 A5 JP2018524270 A5 JP 2018524270A5
Authority
JP
Japan
Prior art keywords
antibody
amino acid
antigen
binding fragment
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017558675A
Other languages
English (en)
Japanese (ja)
Other versions
JP6913030B2 (ja
JP2018524270A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/033155 external-priority patent/WO2016187356A1/en
Publication of JP2018524270A publication Critical patent/JP2018524270A/ja
Publication of JP2018524270A5 publication Critical patent/JP2018524270A5/ja
Priority to JP2021078346A priority Critical patent/JP7072703B6/ja
Application granted granted Critical
Publication of JP6913030B2 publication Critical patent/JP6913030B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017558675A 2015-05-18 2016-05-18 Axlタンパク質に結合する抗体 Active JP6913030B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021078346A JP7072703B6 (ja) 2015-05-18 2021-05-06 Axlタンパク質に結合する抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562163265P 2015-05-18 2015-05-18
US62/163,265 2015-05-18
PCT/US2016/033155 WO2016187356A1 (en) 2015-05-18 2016-05-18 Antibodies that bind to axl proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021078346A Division JP7072703B6 (ja) 2015-05-18 2021-05-06 Axlタンパク質に結合する抗体

Publications (3)

Publication Number Publication Date
JP2018524270A JP2018524270A (ja) 2018-08-30
JP2018524270A5 true JP2018524270A5 (https=) 2019-06-20
JP6913030B2 JP6913030B2 (ja) 2021-08-04

Family

ID=57320574

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017558675A Active JP6913030B2 (ja) 2015-05-18 2016-05-18 Axlタンパク質に結合する抗体
JP2021078346A Active JP7072703B6 (ja) 2015-05-18 2021-05-06 Axlタンパク質に結合する抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021078346A Active JP7072703B6 (ja) 2015-05-18 2021-05-06 Axlタンパク質に結合する抗体

Country Status (5)

Country Link
US (3) US10787517B2 (https=)
EP (2) EP4679095A2 (https=)
JP (2) JP6913030B2 (https=)
ES (1) ES3063952T3 (https=)
WO (1) WO2016187356A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016187354A1 (en) * 2015-05-18 2016-11-24 Agensys, Inc. Antibodies that bind to axl proteins
WO2016187356A1 (en) * 2015-05-18 2016-11-24 Agensys, Inc. Antibodies that bind to axl proteins
US11306153B2 (en) 2016-05-20 2022-04-19 Agency For Science, Technology And Research Anti-AXL tyrosine kinase receptor antibodies and uses thereof

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US7083950B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
EP1732600A2 (en) 2004-03-26 2006-12-20 Pfizer Products Incorporated Uses of anti-ctla-4 antibodies
CA2575791A1 (en) * 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
AU2008323206B2 (en) 2007-11-12 2014-08-14 U3 Pharma Gmbh AXL antibodies
DK2356270T3 (da) 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
EP2408814B1 (en) 2009-03-20 2018-11-21 Amgen Inc. Carrier immunoglobulins and uses thereof
BRPI1013428A2 (pt) 2009-05-11 2019-07-02 U3 Pharma Gmbh anticorpos humanizados para axl
WO2011042548A1 (en) * 2009-10-09 2011-04-14 Sanofi-Aventis Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
BR112012027995A2 (pt) * 2010-06-18 2017-01-10 Genentech Inc anticorpo e ácido nucleíco isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de um indivíduo com câncer, de um indivíduo possuíndo um distúrbio imune, de inibição da angiogênese e para inibir a ativação constitutiva de axl
WO2012141899A1 (en) * 2011-04-14 2012-10-18 Bright View Technologies Corporation Light transmissive structures and fabrication methods for controlling far-field light distribution
CN103747803B (zh) * 2011-06-22 2016-10-12 国家医疗保健研究所 抗axl抗体及其用途
AU2012273954A1 (en) 2011-06-22 2014-01-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-Axl antibodies and uses thereof
US20140121126A1 (en) * 2012-10-25 2014-05-01 Memorial Sloan-Kettering Cancer Center Methods of detecting axl and gas6 in cancer patients
PL2914630T3 (pl) * 2012-11-05 2021-09-06 Pierre Fabre Médicament Nowe białka wiążące antygen i ich zastosowanie jako produktu ukierunkowanego do leczenia raka
WO2016187356A1 (en) * 2015-05-18 2016-11-24 Agensys, Inc. Antibodies that bind to axl proteins
WO2016187354A1 (en) 2015-05-18 2016-11-24 Agensys, Inc. Antibodies that bind to axl proteins
WO2018010140A1 (zh) * 2016-07-14 2018-01-18 中国科学院生物物理研究所 I型干扰素受体抗体及其用途
BR112022017986A2 (pt) * 2020-03-09 2022-12-13 Abcellera Biologics Inc Anticorpos anticoronavírus e métodos de uso
JP2024505636A (ja) * 2021-01-15 2024-02-07 ザ ロックフェラー ユニバーシティー 抗sars-cov-2中和抗体

Similar Documents

Publication Publication Date Title
JP2018525320A5 (https=)
JP2020522261A5 (https=)
JP2018516853A5 (https=)
JP2020500508A5 (https=)
HRP20201928T1 (hr) Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t-stanice, za cd3 i folatni receptor 1 (folr1), i antagonistom vezivanja osi pd-1
JP2019527553A5 (https=)
JPWO2020176678A5 (https=)
NZ601342A (en) Antibodies that bind il-4 and/or il-13 and their uses
RU2018108048A (ru) Новые анти-pd-1 антитела
NZ601858A (en) Methods and compositions for diagnosis and treatment of amyloidosis
JP2016527225A5 (https=)
JP2013091655A5 (https=)
JP2018512379A5 (https=)
JP2020533016A5 (https=)
JP2010536384A5 (https=)
JP2021517152A5 (https=)
IL273196B2 (en) Claudin6 antibodies and methods of treating cancer
PE20221511A1 (es) Anticuerpos anti-ly6g6d y metodos de uso
IL280487B2 (en) Anti-mica/b antibodies that block mica/b shedding and methods of use
MX338694B (es) Composiciones y metodos para el diagnostico y el tratamiento de tumores.
JP2017521054A5 (https=)
JP2017524362A5 (https=)
IL250289B2 (en) Antibodies against angiopoietin-like 4 and methods of use
JP2022500455A5 (https=)
JP2018524270A5 (https=)